Rigel Pharmaceuticals Valuation
| RIGL Stock | USD 35.46 1.18 3.22% |
At this time, the company appears to be undervalued. Rigel Pharmaceuticals holds a recent Real Value of $43.25 per share. The prevailing price of the company is $35.46. Our model determines the value of Rigel Pharmaceuticals from analyzing the company fundamentals such as Shares Outstanding of 18.15 M, return on equity of 2.2, and Operating Margin of 0.41 % as well as examining its technical indicators and probability of bankruptcy. Key fundamental drivers impacting Rigel Pharmaceuticals' valuation include:
Price Book 6.1562 | Enterprise Value | Enterprise Value Ebitda 4.1816 | Price Sales 2.2818 | Forward PE 4.8662 |
Undervalued
Today
Please note that Rigel Pharmaceuticals' price fluctuation is very steady at this time. Calculation of the real value of Rigel Pharmaceuticals is based on 3 months time horizon. Increasing Rigel Pharmaceuticals' time horizon generally increases the accuracy of value calculation and significantly improves the predictive power of the methodology used.
The fair value of the Rigel stock is determined by what a typical buyer is willing to pay for full or partial control of Rigel Pharmaceuticals. Since Rigel Pharmaceuticals is currently traded on the exchange, buyers and sellers on that exchange determine the market value of Rigel Stock. However, Rigel Pharmaceuticals' intrinsic value may or may not be the same as its current market price, in which case there is an opportunity to profit from the mispricing, assuming the market price will eventually merge with its intrinsic value. | Historical | Market 35.46 | Real 43.25 | Target 51.6 | Hype 35.47 | Naive 37.08 |
The intrinsic value of Rigel Pharmaceuticals' stock can be calculated using various methods such as discounted cash flow or dividend analysis. That value may differ from its market price, which is determined by factors such as investor sentiment, market trends, headlines, and other external factors that may influence Rigel Pharmaceuticals' stock price.
Estimating the potential upside or downside of Rigel Pharmaceuticals helps investors to forecast how Rigel stock's addition to their portfolios will impact the overall performance. We also use other valuation drivers to help us estimate the true value of Rigel Pharmaceuticals more accurately as focusing exclusively on Rigel Pharmaceuticals' fundamentals will not take into account other important factors: Traditionally, analysts and sophisticated investors use multiple methods for valuing a cash-flow-generating entity or its stock. For example, some money managers use Rigel Pharmaceuticals' intrinsic value based on its ongoing forecasts of Rigel Pharmaceuticals' financial statements. In contrast, other private, professional wealth advisors use a multiplier approach by looking to relative value analysis against Rigel Pharmaceuticals' closest peers.
Rigel Pharmaceuticals Cash |
|
Rigel Revenue by Product
Rigel Pharmaceuticals Total Value Analysis
Rigel Pharmaceuticals is at this time forecasted to have valuation of 457.06 M with market capitalization of 643.65 M, debt of 59.97 M, and cash on hands of 81.64 M. Please note that valuation may be misleading and is a subject to auditing or accounting errors. We encourage investors to vigilantly validate all of the Rigel Pharmaceuticals fundamentals before making equity appraisal based on enterprise value of the company| Takeover Price | Market Cap | Debt Obligations | Cash |
457.06 M | 643.65 M | 59.97 M | 81.64 M |
Rigel Pharmaceuticals Investor Information
About 91.0% of the company shares are owned by institutional investors. The company recorded earning per share (EPS) of 6.19. Rigel Pharmaceuticals had not issued any dividends in recent years. The entity had 1:10 split on the 27th of June 2024. Based on the key indicators related to Rigel Pharmaceuticals' liquidity, profitability, solvency, and operating efficiency, Rigel Pharmaceuticals is doing better financially today then in previous quarter. It has a moderate odds of reporting better financial numbers in March.Rigel Pharmaceuticals Asset Utilization
The asset utilization indicator refers to the revenue earned for every dollar of assets a company currently reports. Rigel Pharmaceuticals has an asset utilization ratio of 109.33 percent. This suggests that the Company is making $1.09 for each dollar of assets. An increasing asset utilization means that Rigel Pharmaceuticals is more efficient with each dollar of assets it utilizes for everyday operations.Rigel Pharmaceuticals Profitability Analysis
Based on Rigel Pharmaceuticals' profitability indicators, Rigel Pharmaceuticals is performing exceptionally good at this time. It has a great odds to showcase excellent profitability results in March. Profitability indicators assess Rigel Pharmaceuticals' ability to earn profits and add value for shareholders.Net Income | First Reported 2000-03-31 | Previous Quarter 59.6 M | Current Value 27.9 M | Quarterly Volatility 15.9 M |
For Rigel Pharmaceuticals profitability analysis, we use financial ratios and fundamental drivers that measure the ability of Rigel Pharmaceuticals to generate income relative to revenue, assets, operating costs, and current equity. These fundamental indicators attest to how well Rigel Pharmaceuticals utilizes its assets to generate profit and value for its shareholders. The profitability module also shows relationships between Rigel Pharmaceuticals's most relevant fundamental drivers. It provides multiple suggestions of what could affect the performance of Rigel Pharmaceuticals over time as well as its relative position and ranking within its peers.
Rigel Pharmaceuticals Earnings per Share Projection vs Actual
The next projected EPS of Rigel Pharmaceuticals is estimated to be 1.659575 with future projections ranging from a low of 1.635 to a high of 1.6904. Rigel Pharmaceuticals' most recent 12-month trailing earnings per share (EPS TTM) is at 6.19. Please be aware that the consensus of earnings estimates for Rigel Pharmaceuticals is based on EPS before non-recurring items and includes expenses related to employee stock options.Rigel Pharmaceuticals Earnings Estimation Breakdown
The calculation of Rigel Pharmaceuticals' earning per share is based on the data from the past 12 consecutive months, used for reporting the company's financial figures. The next projected EPS of Rigel Pharmaceuticals is estimated to be 1.659575 with the future projection ranging from a low of 1.635 to a high of 1.6904. Please be aware that this consensus of annual earnings estimates for Rigel Pharmaceuticals is based on EPS before non-recurring items and includes expenses related to employee stock options.Last Reported EPS
1.64 Lowest | Expected EPS | 1.69 Highest |
Rigel Pharmaceuticals Earnings Projection Consensus
Suppose the current estimates of Rigel Pharmaceuticals' value are higher than the current market price of the Rigel Pharmaceuticals stock. In this case, investors may conclude that Rigel Pharmaceuticals is overpriced and will exhibit bullish sentiment. On the other hand, if the present value is lower than the stock price, analysts may conclude that the market undervalues the equity. These scenarios may suggest that the market is not as efficient as it should be at the estimation time, and Rigel Pharmaceuticals' stock will quickly adjusts to the new information provided by the consensus estimate.
| Number of Analysts | Historical Accuracy | Last Reported EPS | Estimated EPS for 31st of December 2025 | Current EPS (TTM) | |
| 5 | 34.17% | 1.46 | 1.659575 | 6.19 |
Rigel Pharmaceuticals Ownership Allocation
Rigel Pharmaceuticals owns a total of 18.15 Million outstanding shares. The majority of Rigel Pharmaceuticals outstanding shares are owned by third-party entities. These institutional holders are usually referred to as non-private investors looking to secure positions in Rigel Pharmaceuticals to benefit from reduced commissions. Consequently, institutional investors are subject to a different set of regulations than regular investors in Rigel Pharmaceuticals. Please pay attention to any change in the institutional holdings of Rigel Pharmaceuticals as this could imply that something significant has changed or is about to change at the company. Please note that no matter how many assets the company maintains, if the real value of the company is less than the current market value, you may not be able to make money on it.Rigel Pharmaceuticals Profitability Analysis
The company reported the previous year's revenue of 179.28 M. Net Income was 17.48 M with profit before overhead, payroll, taxes, and interest of 234.38 M.About Rigel Pharmaceuticals Valuation
We use absolute and relative valuation methodologies to arrive at the intrinsic value of Rigel Pharmaceuticals. In general, an absolute valuation paradigm, as applied to this company, attempts to find the value of Rigel Pharmaceuticals based exclusively on its fundamental and basic technical indicators. By analyzing Rigel Pharmaceuticals's financials, quarterly and monthly indicators, and their related drivers, we attempt to find the most accurate representation of Rigel Pharmaceuticals's intrinsic value. As compared to an absolute model, our relative valuation model uses a comparative analysis of Rigel Pharmaceuticals. We calculate exposure to Rigel Pharmaceuticals's market risk, different technical and fundamental indicators, and relevant financial multiples and ratios and then compare them to those of Rigel Pharmaceuticals's related companies.| Last Reported | Projected for Next Year | ||
| Gross Profit | 184.7 M | 194 M | |
| Pretax Profit Margin | 0.09 | 0.10 | |
| Operating Profit Margin | 0.12 | 0.13 | |
| Net Profit Margin | 0.09 | 0.09 | |
| Gross Profit Margin | 0.81 | 0.85 |
Rigel Pharmaceuticals Growth Indicators
Investing in growth stocks can be very risky. If the company such as Rigel Pharmaceuticals does not do well, investors take a loss on the stock when it is time to sell. Also, because growth stocks typically do not pay dividends, the only opportunity an investor has to make money on their investment is when they eventually sell their shares.
| Common Stock Shares Outstanding | 17.7 M | |
| Quarterly Earnings Growth Y O Y | 1.086 | |
| Forward Price Earnings | 4.8662 |
Rigel Pharmaceuticals Current Valuation Indicators
Rigel Pharmaceuticals' valuation analysis is a process of estimating the intrinsic value of all assets and outstanding equities. There are different methodologies and models we use to develop the final Rigel Pharmaceuticals' valuation. The techniques such as discounted cash flow and fundamental indicators such as book value per share or market capitalization are well known and widely used across most financial advisers and money managers.
Valuations are an essential part of business, for companies themselves, but also for investors. For companies, such as Rigel Pharmaceuticals, valuations can help measure their progress and success and can help them track their performance in the market compared to others. In addition, investors can use Rigel Pharmaceuticals' valuations to help determine the worth of potential investments. They can do this by using data and information made public by a company. Regardless of who the valuation is for, it essentially describes Rigel Pharmaceuticals' worth.When determining whether Rigel Pharmaceuticals is a strong investment it is important to analyze Rigel Pharmaceuticals' competitive position within its industry, examining market share, product or service uniqueness, and competitive advantages. Beyond financials and market position, potential investors should also consider broader economic conditions, industry trends, and any regulatory or geopolitical factors that may impact Rigel Pharmaceuticals' future performance. For an informed investment choice regarding Rigel Stock, refer to the following important reports: Check out Your Equity Center to better understand how to build diversified portfolios, which includes a position in Rigel Pharmaceuticals. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in census. For more information on how to buy Rigel Stock please use our How to buy in Rigel Stock guide.You can also try the Commodity Directory module to find actively traded commodities issued by global exchanges.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Rigel Pharmaceuticals. Anticipated expansion of Rigel directly elevates investor willingness to pay premium valuations. The financial industry is built on trying to define current growth potential and future valuation accurately. Comprehensive Rigel Pharmaceuticals assessment requires weighing all these inputs, though not all factors influence outcomes equally.
Quarterly Earnings Growth 1.086 | Earnings Share 6.19 | Revenue Per Share | Quarterly Revenue Growth 0.256 | Return On Assets |
Investors evaluate Rigel Pharmaceuticals using market value (trading price) and book value (balance sheet equity), each telling a different story. Calculating Rigel Pharmaceuticals' intrinsic value - the estimated true worth - helps identify when the stock trades at a discount or premium to fair value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. External factors like market trends, sector rotation, and investor psychology can cause Rigel Pharmaceuticals' market price to deviate significantly from intrinsic value.
It's important to distinguish between Rigel Pharmaceuticals' intrinsic value and market price, which are calculated using different methodologies. Investment decisions regarding Rigel Pharmaceuticals should consider multiple factors including financial performance, growth metrics, competitive position, and professional analysis. Conversely, Rigel Pharmaceuticals' market price signifies the transaction level at which participants voluntarily complete trades.